Source-grounded facts extracted from Bausch Health Companies Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Bausch Health Companies Inc. reported financial results for the quarter ended March 31, 2026.
“Bausch Health Companies Inc. (the "Company") issued a press release announcing results of operations for the quarter ended March 31, 2026 and certain other financial information as of and for the quarter ended March 31, 2026.”
Bausch Health Companies Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank (effective 2026-01-02).
“On January 2, 2026, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc., entered into an amendment (the “Fourth Amendment”) to the Credit and Guaranty Agreement, dated as of May 10, 2022”
Bausch Health Companies Inc. amended term loan of $2,802,125,000 with JPMorgan Chase Bank, N.A. at (i) 3.75% per annum for Replacement Term Loans with an interest rate determined maturing January 15, 2031.
“The Fourth Amendment provides for a new $2,802,125,000 tranche of term loans maturing in 2031 (the "Replacement Term Loans"), the proceeds of which were used to refinance all of Bausch + Lomb’s outstanding term B loans due 2031 (the "Third Amendment Term Loans") and term B loans due 2028 (the "First Incremental Term Loans").”
Bausch Health Companies Inc. incurred senior notes of €675,000,000 aggregate principal amount with Citibank, N.A. at three-month EURIBOR (with a 0% floor) plus 3.875% per year maturing January 15, 2031.
“completed the previously announced offering of €675,000,000 aggregate principal amount of senior secured floating rate notes due 2031 (the “Notes”).”
Jean-Jacques Charhon changed role as Chief Financial Officer and Chief Accounting Officer at Bausch Health Companies Inc..
“until a permanent replacement is in place, at the time that Mr. Barresi ceases to be the Chief Accounting Officer, Jean-Jacques Charhon, who is currently serving as the Company’s Executive Vice President and Chief Financial Officer, will assume the additional role of Chief Accounting Officer.”
John S. Barresi resigned as Senior Vice President, Controller and Chief Accounting Officer at Bausch Health Companies Inc..
“On May 9, 2025, John S. Barresi informed Bausch Health Companies Inc. (the “Company”) of his decision to resign as the Senior Vice President, Controller and Chief Accounting Officer of the Company.”
John S. Barresi changed role as Senior Vice President, Controller and Chief Accounting Officer at Bausch Health Companies Inc..
“John S. Barresi, who has served as the Company’s interim Chief Financial Officer since October 2023, will no longer act in this capacity and will continue in his role as Senior Vice President, Controller and Chief Accounting Officer.”
Jean-Jacques Charhon was appointed as Executive Vice President and Chief Financial Officer at Bausch Health Companies Inc..
“On July 15, 2024, the Board of Directors (the “Board”) of Bausch Health Companies Inc. (the “Company”) appointed Jean-Jacques Charhon as the Company’s Executive Vice President and Chief Financial Officer, effective as of August 19, 2024.”
Bausch Health Companies Inc. shareholders approved Appointment of the Independent Registered Public Accounting Firm at the 2024-05-14 meeting.
“The shareholders appointed PricewaterhouseCoopers LLP as the auditors for the Company to hold office until the close of the 2024 Annual Meeting of Shareholders and authorized the Company’s Board of Directors to fix the auditors’ remuneration. For Withheld 252,834,132 10,389,131”
Bausch Health Companies Inc. shareholders approved Advisory Vote on Executive Compensation at the 2024-05-14 meeting.
“The shareholders approved, on a non-binding advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Compensation Discussion and Analysis section, executive compensation tables and accompanying narrative discussions contained in the Management Proxy Circular and Proxy Statement. For Against Abstain Broker Non-Votes I 78,660,733 5,195,531 8,435,696 70,931,303”
Bausch Health Companies Inc. shareholders approved Election of Directors at the 2024-05-14 meeting.
“The shareholders elected the following individuals to the Company’s Board of Directors, to serve until the close of the Company’s 2025 Annual Meeting of Shareholders, their successors are duly elected or appointed, or such director’s earlier resignation or removal: Name For Withheld Broker Non-Votes Thomas J. Appio 181,373,219 10,918,741 70,931,303 Christian A. Garcia 181,143,285 11,148,675 70,931,303 Brett M. Icahn 170,144,670 22,147,290 70,931,303 Sarah B. Kavanagh 180,316,464 11,975,496 70,931,303 Frank D. Lee 173,147,642 19,144,318 70,931,303 Steven D. Miller 177,700,669 14,591,291 70,931,303 Richard C. Mulligan, Ph.D. 175,256,854 17,035,106 70,931,303 John A. Paulson 179,422,691 12,869,269 70,931,303 Robert N. Power 173,228,670 19,063,290 70,931,303 Amy B. Wechsler, M.D. 181,626,477 10,665,483 70,931,303”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.